



Short Communication

Immunomodulatory effects of zinc and its impact on COVID-19 severity

Manish Dhawan^{a,b}, Talha Bin Emran^c, Priyanaka^d, Om Prakash Choudhary^{e,*}^a Department of Microbiology, Punjab Agricultural University, Ludhiana-141004, India^b Trafford College, Altrincham, Manchester, WA14 5PQ, UK^c Department of Pharmacy, BGC Trust University Bangladesh, Chittagong, 4381, Bangladesh^d Independent Researcher, 07, Type Iv Quarter, College of Veterinary Sciences and Animal Husbandry, Central Agricultural University (I), Selesih, Aizawl, India^e Department of Veterinary Anatomy and Histology, College of Veterinary Sciences and Animal Husbandry, Central Agricultural University (I), Selesih, Aizawl, India

ARTICLE INFO

Keywords:

COVID-19

SARS-CoV-2

Cytokines

Immunomodulation

Zinc

ABSTRACT

The COVID-19 pandemic has led to severe financial, clinical, and societal repercussions and imposed more pressure on the healthcare system of many nations. COVID-19 impacts the immune system by causing a systemic inflammatory reaction, often known as cytokine release syndrome (CRS). COVID-19 patients had elevated levels of pro-inflammatory cytokines and chemokines. In this context, many dietary interventions have been utilized to mitigate the adverse effects of COVID-19 by regulating the excessive secretion of cytokines and chemokines. Zinc, an anti-inflammatory and antioxidant mineral in food with a well-established role in immunity, is now being employed in several clinical studies against COVID-19. Zn deficiency has been correlated with the increased production of pro-inflammatory cytokines. As a result, we will summarise zinc's immunomodulatory effects in this article. We will investigate how zinc deficiency might contribute to a poor prognosis of COVID-19 disease by altering the release of particular cytokines.

1. Introduction

The COVID-19 (Coronavirus Disease 2019) pandemic has claimed the lives of over 5.5 million people worldwide, along with causing severe problems to healthcare facilities and medical infrastructure [1]. Due to a lack of efficient therapeutic candidates, the world is having a difficult time battling this outbreak. Many research groups have developed COVID-19 vaccines such as mRNA vaccines, DNA vaccines, viral vector vaccines, virus-like particles (VLPs), recombinant vaccines, protein subunit-based vaccines, live attenuated and inactivated virus vaccines after a substantial amount of effort [2,3]. These vaccines are being employed to vaccinate people in various nations under national vaccination programs [4,5]. Various vaccines in use have demonstrated a high level of effectiveness, with varied protection values of up to 95% (70–95% range) in immunized persons against COVID-19 [6,7].

Because there are currently no approved medicines for the treatment of COVID-19, non-pharmaceutical strategies such as social distancing, public cleanliness, and the use of facial masks remain the best available options for the prevention of any possible outbreak [8]. In addition, various mutations have been identified and reported in its causative agent, i.e., SARS-CoV-2. Mutations in SARS-CoV-2 variants may alter the

neutralizing activity of vaccine-elicited antibodies and monoclonal antibodies (MABs), resulting in a mild-to-significant loss of effectiveness. Furthermore, these viral alterations may significantly impact the dissemination capabilities of the virus, therapeutic efficacy, and diagnostic processes [9,10]. As a result, finding an alternative therapeutic regimen is critical at this time to reduce the negative repercussions of any future COVID-19 instances.

According to recent studies, certain nutritional supplements may be effective in COVID-19 patients. Higher-than-recommended daily doses of micronutrients, including vitamins and zinc, may have a beneficial effect, possibly lowering the viral load and length of hospitalization in patients with COVID-19 [11,12]. Surprisingly, a recent comprehensive analysis of randomized controlled trials discovered that relatively few research substantiates the favorable effects of zinc supplementation. As a result, zinc supplementation-based COVID-19 prevention or treatment treatments are currently speculative. However, if the outcomes of ongoing clinical studies are disclosed, the real conclusions can be revised and used to give improved treatment approaches to control SARS-CoV-2 infection [13].

It is important to consider that the micronutrients were shown to have immunomodulatory effects and to lessen the adverse effects of a

* Corresponding author. Department of Veterinary Anatomy and Histology, College of Veterinary Sciences and Animal Husbandry, Central Agricultural University (I), Selesih, Aizawl, 796015, Mizoram, India.

E-mail address: dr.om.choudhary@gmail.com (O.P. Choudhary).

<https://doi.org/10.1016/j.amsu.2022.103638>

Received 3 April 2022; Received in revised form 13 April 2022; Accepted 13 April 2022

Available online 16 April 2022

2049-0801/© 2022 The Authors. Published by Elsevier Ltd on behalf of IJS Publishing Group Ltd. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

variety of diseases. Hence, it is crucial to uncover that how deficiencies of micronutrients such as Zn and Selenium (Se) can lead to immune dysfunction and increased susceptibility to viral infections [8]. In viral diseases, micronutrient deficiencies have been associated with poor treatment outcomes. Undernourished people with the risk of or confirmed with COVID-19 can benefit from regular consumption of supplements and trace minerals to boost their immune response and build their resistance against viral infections. A recent study discovered vitamin D, zinc, and selenium deficiencies in COVID-19 patients with acute respiratory tract infections [8,14].

Recently, zinc has been identified as one of the critical micronutrients to provide supportive treatment in COVID-19 patients due to its immunomodulatory and antiviral properties. The efficacy and reliability of various treatments, such as hydroxychloroquine can be increased with zinc supplementation [15]. Moreover, improvements have been recorded in COVID-19 patients (clinical and symptomatic) treated with high-dose zinc [16]. Many studies have suggested that zinc supplementation can reduce the symptoms such as lower respiratory tract infection in patients with COVID-19. In addition, it has been postulated that the zinc may suppress viral uncoating, binding, and replication [11,17] which may help in the reduction of the viral load in severely infected patients with COVID-19. Apart from the anti-inflammatory action of zinc, antioxidant effects can also reduce the devastating consequences of COVID-19. As a result, the following section aims to look into the immunomodulatory effects of zinc.

2. Immunomodulatory effects of zinc

Zinc has been associated with the development and functional activity of various essential cells of the innate immune response, such as neutrophils and natural killer cells (NK cells). However, zinc deficiency may inhibit the production of cytokines and can significantly inhibit the adaptive and innate immune response [18]. There is no doubt that the balance of anti-inflammatory and pro-inflammatory cytokines is an essential component in the SARS-CoV-2 infection. Hence, zinc can play a crucial role in SARS-CoV-2 infection by regulating cytokine release. Moreover, a balance of Zn concentration in the human body is necessary for fighting against viral infection. In addition, zinc also helps in providing defense against the overactive immune system that causes severe allergies and autoimmune illnesses. Hence, zinc operates as a gatekeeper for the optimal functioning of immune cells and helps in providing an appropriate amount of immune response. In addition, the anti-oxidative characteristics of zinc can defend lung cells against free radicals induced harm amid inflammatory response [19] due to increased release of cytokines and chemokines.

Zinc is an essential micronutrient for the chemotactic activity of innate immune cells such as NK (Natural killer) cells and neutrophils. Zinc has a significant role in recruiting neutrophils and positively affects the phagocytic activity of antigen-presenting cells (APCs). Zinc deficiency can lower lymphocyte counts and hampers the efficient functioning of CD4⁺ and CD8⁺ T cells. Nevertheless, intake of zinc increases the number of T cells and NK cells and the production of IL-2 and soluble IL-2 receptors. These Zinc immunomodulatory effects can help suppress coronavirus synthesis, replication, and transcription [11,20]. In addition, zinc can interfere with viral multiplication and protein translation, giving antiviral benefits and pharmacological properties [21].

Zn is well known for its anti-inflammatory activities, but it is essential to consider that zinc also possesses antioxidant and membrane stabilizing activities [22,23]. Therefore, immune cell survival might be hampered by zinc deprivation, which also impacts essential processes like phagocytosis, target cell death, and cytokine synthesis. Preclinical studies have shown that Zn deficiency leads to the thymus and lymphoid tissues degeneration [24] as well as reductions in the processes of Th (T helper) cells [25]. In addition, the cytotoxic effects of CD8⁺ T cells can be impaired due to the lesser concentration of zinc in the human body [21,26]. Zn deficiency causes immune system dysfunction, as indicated

by thymus degradation, lymphopenia, and impaired immunologic response of lymphocytes [22,27,28]. Immunodeficiency, along with the significant reduction in the lymphocytes, can be resulted from Zn deficiency, which is characterized by a considerable decrease in growing B cell compartments inside the bone marrow [27–29]. Furthermore, the optimum concentration of zinc can increase the IFN- α effect [25,30], which can be employed to reverse the reduction of IFNs secretion by SARS-CoV-2 proteins [23,30,31]; hence the zinc deficiency can lead to poor prognosis of the COVID-19 disease [23].

In vitro studies have shown that Zn deficiency can lead to the increased production of IL-6 and IL-1, which are the crucial cytokines in the initiation of cytokines release. In addition, higher expression of intercellular adhesion molecule 1 (ICAM-1) has been reported, which is vital for leukocyte extravasation of CD86 [31]. Reduced plasma Zn levels can be associated with increased IL-6 and ICAM-1 gene expression in splenocytes [26,31]; hence, Zn supplementation may be beneficial in reducing inflammatory cytokines, particularly IL-6 and IL-1. In addition, zinc can enhance the secretion of IFN type-1 cytokines [11,32], which is suppressed in patients with severe COVID-19. Beneficial cytokines such as IFN type-1 and IL-7 are essential to generate an appropriate immune response to apparent viral infection [33]. On the other hand, IL-6 and TNF- α are considered harmful cytokines [33,34], which have been reported higher under zinc deficiency [31].

Patients with COVID-19 who had lower zinc levels on arrival to the hospital had a greater mortality risk [35]. As a result, it has been proposed that transient zinc deficiency during SARS-CoV-2 infection can lead to hyperinflammation. Zinc's anti-inflammatory response, on the other hand, has been demonstrated by a reduction in I κ B kinase response, modification of T-cell function, and NF- κ B signaling, as well as a drop in pro-inflammatory cytokines [36]. Furthermore, zinc therapy has been shown to reduce inflammatory cytokines (IL-1 and IL-6), enhancing type-I IFN response [37]. Hence, using zinc supplementation along with other therapeutic regimens can be proven as a more effective strategy to combat viral infections like SARS-CoV-2 [23,38].

3. Conclusion and future perspective

Many studies have demonstrated that boosting the immune response with micronutrients during SARS-CoV-2 infection can help to reduce viral load and reduce the risk of hospitalization. Supplementing increased doses of micronutrients like vitamin D and zinc during COVID-19 infection may be beneficial. Zinc deficiency can lead to increased levels of specific crucial pro-inflammatory cytokines such as IL-6 and IL-1. At the same time, Zinc supplementation can induce the type I IFN immune response, which has been considered critical in reducing the excessive release of cytokines, a key characteristic of patients with severe COVID-19. Aside from the fact that nutritional supplementation is usually cost-effective, research has linked zinc, vitamin D, and vitamin C to anti-inflammatory and anti-oxidative properties. A lack of these nutraceutical supports has been linked to the poor prognosis of the COVID-19 disease.

Till now, more than 50 clinical trials have been reported with the goal of using zinc supplementation as a therapeutic or preventative approach. The results of ongoing clinical trials will be critical in validating the efficacy of zinc as an alternative strategy to treat SARS-CoV-2 infection. Furthermore, more research is needed to determine the optimal dosage of micronutrients like zinc to prevent people from COVID-19 or ease symptoms. In order to further understand the effect of diet on illness outcomes, other critical immunomodulatory micronutrients must be investigated.

Ethical approval

This article does not require any human/animal subjects to acquire such approval.

Sources of funding

This study received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors.

Author contribution

Manish Dhawan: Conceptualization, Data Curation, Visualization, Writing - Original Draft, Writing - review & editing. Talha Bin Emran: Writing - Original Draft, Writing - review & editing. Priyanka: Writing - Original Draft, Writing - review & editing. Om Prakash Choudhary: Conceptualization, Writing - Original Draft, Writing - review & editing. All authors critically reviewed and approved the final version of the manuscript.

Registration of research studies

Name of the registry: Not applicable

Unique Identifying number or registration ID: Not applicable

Hyperlink to your specific registration (must be publicly accessible and will be checked): Not applicable

Guarantor

Om Prakash Choudhary, Assistant Professor, Department of Veterinary Anatomy and Histology, College of Veterinary Sciences and Animal Husbandry, Central Agricultural University (I), Selesih, Aizawl-796,015, Mizoram, India. Tel: +91-9928099090; Email: dr.om.choudhary@gmail.com.

Consent

Not applicable.

Provenance and peer review

Not commissioned, externally peer reviewed.

Declaration of competing interest

All authors report no conflicts of interest relevant to this article.

References

- M. Dhawan, Priyanka, M. Parmar, S. Angural, O.P. Choudhary, Convalescent plasma therapy against the emerging SARS-CoV-2 variants: delineation of the potentialities and risks, *Int. J. Surg.* 97 (2022) 106204, <https://doi.org/10.1016/j.ijsu.2021.106204>.
- M. Iqbal Yatoo, Z. Hamid, O.R. Parray, A.H. Wani, A. Ul Haq, A. Saxena, S.K. Patel, M. Pathak, R. Tiwari, Y.S. Malik, R. Sah, A.A. Rabaan, A.J. Rodriguez Morales, K. Dhama, COVID-19- recent advancements in identifying novel vaccine candidates and current status of upcoming SARS-CoV-2 vaccines, *Hum. Vaccines Immunother.* 16 (12) (2020) 2891–2904, <https://doi.org/10.1080/21645515.2020.1788310>.
- K. Dhama, M. Dhawan, R. Tiwari, T.B. Emran, S. Mitra, A.A. Rabaan, S. Alhumaid, Z.A. Alawi, A. Al Mutair, COVID-19 intranasal vaccines: current progress, advantages, prospects, and challenges, *Hum. Vaccines Immunother.* 8 (2022) 1–11, <https://doi.org/10.1080/21645515.2022.2045853>.
- M. Dhawan, K. Dhama, M. Parmar, A. Sharma, S. Angural, Unravelling the potentialities of tocilizumab for the development of a potential immunotherapeutic regimen against COVID-19: A narrative review, *J. Appl. Pharmaceut. Sci.* 11 (11) (2021) 26–33, <https://doi.org/10.7324/JAPS.2021.1101104>.
- M. Dhawan, Priyanka, A. Sahni, O.P. Choudhary, Vaccine inequity and hesitancy: dual factors in the emergence of novel SARS-CoV-2 variants, *Ann. Med. Surg.* 73 (2022), 103186, <https://doi.org/10.1016/j.amsu.2021.103186>.
- D.M. Skowronski, G. De Serres, Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine, *N. Engl. J. Med.* 384 (16) (2021) 1576–1577, <https://doi.org/10.1056/NEJMc2036242>.
- M.D. Knoll, C. Wonodi, Oxford-AstraZeneca COVID-19 vaccine efficacy, *Lancet* 397 (10269) (2021) 72–74, [https://doi.org/10.1016/S0140-6736\(20\)32623-4](https://doi.org/10.1016/S0140-6736(20)32623-4).
- M. Dhawan, Priyanka, O.P. Choudhary, Immunomodulatory and therapeutic implications of vitamin D in the management of COVID-19, *Hum. Vaccines Immunother.* 18 (1) (2022), e2025734, <https://doi.org/10.1080/21645515.2022.2025734>.
- M. Dhawan, Priyanka, O.P. Choudhary, Omicron SARS-CoV-2 variant: reasons of emergence and lessons learnt, *Int. J. Surg.* 97 (2022) 106198, <https://doi.org/10.1016/j.ijsu.2021.106198>.
- O.P. Choudhary, M. Dhawan, Priyanka, Omicron variant (B.1.1.529) of SARS-CoV-2: threat assessment and plan of action, *Int. J. Surg.* 97 (2022) 106187, <https://doi.org/10.1016/j.ijsu.2021.106187>.
- H. Shakoor, J. Feehan, A.S. Al Dhaheri, H.I. Ali, C. Platat, L.C. Ismail, V. Apostolopoulos, L. Stojanovska, Immune-boosting role of vitamins D, C, E, zinc, selenium and omega-3 fatty acids: could they help against COVID-19? *Maturitas* 143 (2021) 1–9, <https://doi.org/10.1016/j.maturitas.2020.08.003>.
- A.F. Gombart, A. Pierre, S. Maggini, A review of micronutrients and the immune system-working in harmony to reduce the risk of infection, *Nutrients* 12 (1) (2020) 236, <https://doi.org/10.3390/nu12010236>.
- E. Balboni, F. Zagnoli, T. Filippini, S.J. Fairweather-Tait, M. Vinceti, Zinc and selenium supplementation in COVID-19 prevention and treatment: a systematic review of the experimental studies, *J. Trace Elem. Med. Biol.* 71 (2022), 126956, <https://doi.org/10.1016/j.jtemb.2022.126956>.
- M. Bae, H. Kim, Mini-review on the roles of vitamin C, vitamin D, and selenium in the immune system against COVID-19, *Molecules* 25 (22) (2020) 5346, <https://doi.org/10.3390/molecules25225346>.
- M.T. Rahman, S.Z. Idid, Can Zn be a critical element in COVID-19 treatment? *Biol. Trace Elem. Res.* 199 (2) (2021) 550–558, <https://doi.org/10.1007/s12011-020-02194-9>.
- E. Finzi, Treatment of SARS-CoV-2 with high dose oral zinc salts: a report on four patients, *Int. J. Infect. Dis.* 99 (2020) 307–309, <https://doi.org/10.1016/j.ijid.2020.06.006>.
- K.K. Pvsn, S. Tomo, P. Purohit, S. Sankanagoudar, J. Charan, A. Purohit, V. Nag, P. Bhatia, K. Singh, N. Dutt, M.K. Garg, P. Sharma, S. Misra, D. Yadav, Comparative analysis of serum Zinc, Copper and Magnesium level and their relations in association with severity and mortality in SARS-CoV-2 patients, *Biol. Trace Elem. Res.* 22 (2022) 1–8, <https://doi.org/10.1007/s12011-022-03124-7>.
- A.S. Prasad, Zinc in human health: effect of zinc on immune cells, *Mol. Med.* 14 (5–6) (2008) 353–357, <https://doi.org/10.2119/2008-00033.Prasad>.
- I. Wessels, M. Maywald, L. Rink, Zinc as a gatekeeper of immune function, *Nutrients* 9 (12) (2017) 1286, <https://doi.org/10.3390/nu9121286>.
- A.J. te Velthuis, S.H. van den Worm, A.C. Sims, R.S. Baric, E.J. Snijder, M.J. van Hemert, Zn(2+) inhibits coronavirus and arterivirus RNA polymerase activity in vitro and zinc ionophores block the replication of these viruses in cell culture, *PLoS Pathog.* 6 (11) (2010), e1001176, <https://doi.org/10.1371/journal.ppat.1001176>.
- A.V. Skalny, L. Rink, O.P. Ajsuvakova, M. Aschner, V.A. Gritsenko, S.I. Alekseenko, A.A. Svistunov, D. Petrakis, D.A. Spandidos, J. Aaseth, A. Tsatsakis, A.A. Tinkov, Zinc and respiratory tract infections: perspectives for COVID-19 (review), *Int. J. Mol. Med.* 46 (1) (2020) 17–26, <https://doi.org/10.3892/ijmm.2020.4575>.
- A.S. Prasad, Zinc: role in immunity, oxidative stress and chronic inflammation, *Curr. Opin. Clin. Nutr. Metab. Care* 12 (6) (2009) 646–652, <https://doi.org/10.1097/mco.0b013e32833312956>.
- A. Pal, R. Squitti, M. Picozza, A. Pawar, M. Rongioletti, A.K. Dutta, S. Sahoo, K. Goswami, P. Sharma, R. Prasad, Zinc and COVID-19: basis of current clinical trials, *Biol. Trace Elem. Res.* 199 (8) (2021) 2882–2892, <https://doi.org/10.1007/s12011-020-02437-9>.
- A.H. Shankar, A.S. Prasad, Zinc and immune function: the biological basis of altered resistance to infection, *Am. J. Clin. Nutr.* 68 (2) (1998) 447S–463S, <https://doi.org/10.1093/ajcn/68.2.447s>.
- P.J. Fraker, P. DePasquale-Jardieu, C.M. Zwickl, R.W. Luecke, Regeneration of T-cell helper function in zinc-deficient adult mice, *Proc. Natl. Acad. Sci. U.S.A.* 75 (11) (1978) 5660–5664, <https://doi.org/10.1073/pnas.75.11.5660>.
- P. Frost, P. Rabbani, J. Smith, A. Prasad, Cell-mediated cytotoxicity and tumor growth in zinc-deficient mice, *Proc. Soc. Exp. Biol. Med.* 167 (3) (1981) 333–337, <https://doi.org/10.3181/00379727-167-41174>.
- T. Fukada, S. Hojo, T. Hara, T. Takagishi, Revisiting the old and learning the new of zinc in immunity, *Nat. Immunol.* 20 (3) (2019) 248–250, <https://doi.org/10.1038/s41590-019-0319-z>.
- S. Gupta, S.A. Read, N.A. Shackel, L. Hebbard, J. George, G. Ahlenstiel, The role of micronutrients in the infection and subsequent response to Hepatitis C Virus, *Cells* 8 (6) (2019) 603, <https://doi.org/10.3390/cells8060603>.
- P. Bonaventura, G. Benedetti, F. Albarède, P. Miossec, Zinc and its role in immunity and inflammation, *Autoimmun. Rev.* 14 (4) (2015) 277–285, <https://doi.org/10.1016/j.autrev.2014.11.008>.
- K. Berg, G. Bolt, H. Andersen, T.C. Owen, Zinc potentiates the antiviral action of human IFN-alpha tenfold, *J. Interferon Cytokine Res.* 21 (7) (2001) 471–474, <https://doi.org/10.1089/10799900152434330>.
- C.P. Wong, N.A. Rinaldi, E. Ho, Zinc deficiency enhanced inflammatory response by increasing immune cell activation and inducing IL6 promoter demethylation, *Mol. Nutr. Food Res.* 59 (5) (2015) 991–999, <https://doi.org/10.1002/mnfr.201400761>.
- F.W. Beck, A.S. Prasad, J. Kaplan, J.T. Fitzgerald, G.J. Brewer, Changes in cytokine production and T cell subpopulations in experimentally induced zinc-deficient humans, *Am. J. Physiol.* 272 (6) (1997) E1002–E1007, <https://doi.org/10.1152/ajpendo.1997.272.6.E1002>.
- A.A. Rabaan, S.H. Al-Ahmed, J. Muhammad, A. Khan, A.A. Sule, R. Tirupathi, A. A. Mutair, S. Alhumaid, A. Al-Omari, M. Dhawan, R. Tiwari, K. Sharun, R. K. Mohapatra, S. Mitra, M. Bilal, S.A. Alyami, T.B. Emran, M.A. Moni, K. Dhama, Role of inflammatory cytokines in COVID-19 patients: a review on molecular mechanisms, immune functions, immunopathology and immunomodulatory drugs

- to counter cytokine storm, *Vaccines* 9 (5) (2021 Apr 29) 436, <https://doi.org/10.3390/vaccines9050436>.
- [34] A.A. Rabaan, S.H. Al-Ahmed, M.A. Garout, A.M. Al-Qaaneh, A.A. Sule, R. Tirupathi, A.A. Mutair, S. Alhumaid, A. Hasan, M. Dhawan, R. Tiwari, K. Sharun, R.K. Mohapatra, S. Mitra, T.B. Emran, M. Bilal, R. Singh, S.A. Alyami, M.A. Moni, K. Dhama, Diverse immunological factors influencing pathogenesis in patients with COVID-19: a review on viral dissemination, immunotherapeutic options to counter cytokine storm and inflammatory responses, *Pathogens* 10 (5) (2021) 565, <https://doi.org/10.3390/pathogens10050565>.
- [35] D. Jothimani, E. Kailasam, S. Danielraj, B. Nallathambi, H. Ramachandran, P. Sekar, S. Manoharan, V. Ramani, G. Narasimhan, I. Kaliamoorthy, M. Rela, COVID-19: poor outcomes in patients with zinc deficiency, *Int. J. Infect. Dis.* 100 (2020) 343–349, <https://doi.org/10.1016/j.ijid.2020.09.014>.
- [36] I. Wessels, H. Haase, G. Engelhardt, L. Rink, P. Uciechowski, Zinc deficiency induces production of the proinflammatory cytokines IL-1 β and TNF α in promyeloid cells via epigenetic and redox-dependent mechanisms, *J. Nutr. Biochem.* 1 (2013) 289–297, <https://doi.org/10.1016/j.jnutbio.2012.06.007>.
- [37] S. Corrao, R. Mallaci Bocchio, M. Lo Monaco, G. Natoli, A. Cavezzi, E. Troiani, C. Argano, Does evidence exist to blunt inflammatory response by nutraceutical supplementation during COVID-19 pandemic? an overview of systematic reviews of Vitamin D, Vitamin C, Melatonin, and Zinc, *Nutrients* 13 (4) (2021) 1261, <https://doi.org/10.3390/nu13041261>.
- [38] L. Borges, M. Gennari-Felipe, B.B. Dias, E. Hatanaka, Melatonin, Zinc, and Vitamin C: potential adjuvant treatment for COVID-19 patients, *Front. Nutr.* 8 (2022), 821824, <https://doi.org/10.3389/fnut.2021.821824>.